PriceTargets.com logo

Entera Bio - ENTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $9.60
  • Forecasted Upside: 200.00%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$3.20 As of 10/30/2026 05:00 PM ET
▲ +0.08 (2.56%)

This chart shows the closing price for ENTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Entera Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENTX

Analyst Price Target is $9.60
▲ +200.00% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Entera Bio in the last 3 months. The average price target is $9.60, with a high forecast of $11.00 and a low forecast of $9.00. The average price target represents a 200.00% upside from the last price of $3.20.

This chart shows the closing price for ENTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 6 polled investment analysts is to moderate buy stock in Entera Bio. This rating has held steady since August 2026, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/1/2026
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/30/2026
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/30/2026

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/15/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/24/2026GuggenheimInitiated CoverageBuy$11.00
9/24/2026GuggenheimUpgradeStrong-Buy
9/23/2026Lifesci CapitalInitiated CoverageOutperform$10.00
9/22/2026Cantor FitzgeraldInitiated CoverageOverweight
9/18/2026UBS GroupSet Target$9.00
9/18/2026Leerink PartnersInitiated CoverageOutperform$9.00
7/17/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/24/2026HC WainwrightReiterated RatingBuy ➝ Buy
4/27/2026HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $9.00
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
2/9/2026HC WainwrightReiterated RatingBuy ➝ Buy$10.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/11/2025HC WainwrightUpgradeStrong-Buy
3/18/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
10/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
9/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
6/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
4/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
12/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00
9/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00
4/4/2023HC WainwrightReiterated RatingBuy$10.00
3/28/2023HC WainwrightReiterated RatingBuy$10.00
9/6/2022HC WainwrightInitiated CoverageBuy$10.00
7/19/2022B. Riley FinancialLower TargetBuy$6.00 ➝ $5.00
1/24/2022B. Riley FinancialLower Target$11.00 ➝ $6.00
(Data available from 10/31/2021 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2026
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2026
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/2/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2026
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2026

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Entera Bio logo
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Read More

Today's Range

Now: $3.20
Low: $2.95
High: $3.24

50 Day Range

MA: $2.90
Low: $2.49
High: $3.47

52 Week Range

Now: $3.20
Low: $0.91
High: $4.20

Volume

291,682 shs

Average Volume

635,115 shs

Market Capitalization

$556.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Entera Bio?

The following sell-side analysts have issued research reports on Entera Bio in the last twelve months: Cantor Fitzgerald, Guggenheim, HC Wainwright, Leerink Partners, Lifesci Capital, UBS Group AG, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for ENTX.

What is the current price target for Entera Bio?

0 Wall Street analysts have set twelve-month price targets for Entera Bio in the last year. Their average twelve-month price target is $9.60, suggesting a possible upside of 200.0%. Guggenheim has the highest price target set, predicting ENTX will reach $11.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $9.00 for Entera Bio in the next year.
View the latest price targets for ENTX.

What is the current consensus analyst rating for Entera Bio?

Entera Bio currently has 1 sell rating, 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ENTX.

What other companies compete with Entera Bio?

Other companies that are similar to Entera Bio include Lakefront Biotherapeutics American Depositary Shares, Pharvaris, BioCryst Pharmaceuticals, Septerna and Zymeworks. Learn More about companies similar to Entera Bio.

How do I contact Entera Bio's investor relations team?

Entera Bio's physical mailing address is Kiryat Hadassah Minrav Building, Jerusalem, JM, 9112002. The company's listed phone number is (722) 532-7151 and its investor relations email address is [email protected]. The official website for Entera Bio is www.enterabio.com. Learn More about contacing Entera Bio investor relations.